The Swiss synthetic biology company, Evolva Holding SA, has raised CHF 31.3 million (€25.7 million) in a share placement with existing and new investors in order to support its portfolio of nutritional and pharmaceutical products. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
